Summary:
Click image to enlarge
A Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study of LY4100511 (DC-853) for the treatment of adult participants with moderate-to-severe plaque psoriasis.
Qualified Participants Must:
• Between 18 to 70 years old (inclusive)
•
Diagnosed with moderate to severe plaque psoriasis for at least 6 months prior to screening
•
Overall healthy with BMI of 18-40 kg/m2
•
Must be a candidate for phototherapy, as assessed by the investigator
Qualified Participants May Receive:
Qualified participants may receive reimbursement for their time and travel.